CM
PRCT icon

Castleark Management’s Procept Biorobotics PRCT Stock Holding History

Castleark Management’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-43,250
Closed -$3.47M – 322
2024
Q3 		$3.47M Sell
43,250
-49,990
-54% -$3.55M 0.14% 145
2024
Q2 		$5.7M Buy
93,240
+35,750
+62% +$2.13M 0.23% 102
2024
Q1 		$2.84M Buy
+57,490
New +$2.74M 0.12% 160
2023
Q1 		– Sell
-67,960
Closed -$2.82M – 315
2022
Q4 		$2.82M Buy
67,960
+1,060
+2% +$45.5K 0.15% 144
2022
Q3 		$2.77M Buy
+66,900
New +$2.67M 0.15% 136

Other funds holding PRCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Castleark Management's PRCT Position: Q4 2024 in Review

Castleark Management sold out of Procept Biorobotics (PRCT) in Q4 2024, closing a stake of 43,250 shares — an estimated $3.47M sold.

Castleark Management first reported a position in PRCT in Q3 2022 and held it in 5 quarters. The position peaked at $5.7M in Q2 2024. 281 funds tracked by Wall St. Rank hold PRCT as of Q4 2024.

  • Castleark Management reported no remaining Procept Biorobotics position as of Q4 2024 after selling out during the quarter.
  • Castleark Management sold 43,250 Procept Biorobotics shares in Q4 2024, an estimated $3.47M.
  • Castleark Management first reported a position in Procept Biorobotics in Q3 2022 and held it in 5 quarters.
  • Castleark Management's Procept Biorobotics position peaked at $5.7M in Q2 2024.
  • 281 funds tracked by Wall St. Rank held Procept Biorobotics as of Q4 2024.

Based on Castleark Management's 13F filing for Q4 2024, filed 18 Feb 2025.